Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of June 2020, with a specific transaction date of June 15, 2020. The report serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) under the UK Disclosure Guidance and Transparency Rules.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. It details a specific executive compensation event:
- Executive: Ms. D Waterhouse, CEO of ViiV Healthcare.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Final vesting of a Deferred Investment Award made on June 15, 2017.
- Volume: 4,720.419 notional Ordinary Shares.
- Price: 16.008 (currency not explicitly stated in the price field, but context implies GBP).
- Settlement: Cash payment of £75,564.47 (less applicable tax withholding).
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely documents the settlement of a pre-existing equity award plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of a specific transaction.
Key Facts for Investor Verification
- Verify the tax withholding amount deducted from the gross cash payment of £75,564.47.
- Confirm the share price of 16.008 aligns with the market price on June 15, 2020.
- Note that this transaction resulted in a cash payout rather than the issuance of new shares to the executive.